Australian software automates data mining of CR dose

Sep 8, 2009

2009 09 04 13 32 21 103 Snapshot 700

2009 09 04 13 32 21 103 Snapshot 700

The dose data-mining software analyzes CR exposure indices, highlighting underexposed studies in blue and overexposed exams in red. Image courtesy of Curtise Ng, Ph.D.

New PET tracer show promise in neuroblastoma

July 9, 2026

PreludeDx, Learn Look Locate launch DCIS patient education resource

July 9, 2026

Philips Rsna 2021 400

Philips, U of Washington explore AI for non-contrast breast MRI

July 9, 2026

Blue Earth, UCL dose first patient in Ac-225 PSMA prostate trial

July 9, 2026

New PET tracer show promise in neuroblastoma

F-18 mFBG achieved a pooled sensitivity of 97%, compared with 82% for I-123 MIBG.

July 9, 2026

PreludeDx, Learn Look Locate launch DCIS patient education resource

By AuntMinnie.com staff writers

The patient-centered guide will cover various aspects of DCIS, including recurrence risk and radiation therapy decision-making.

July 9, 2026

Philips, U of Washington explore AI for non-contrast breast MRI

By AuntMinnie.com staff writers

University researchers will use Philips' Paradise AI research platform to develop models.

July 9, 2026

Philips Rsna 2021 400

Blue Earth, UCL dose first patient in Ac-225 PSMA prostate trial

By AuntMinnie.com staff writers

The study is evaluating an investigational alpha-emitting PSMA-targeted radiopharmaceutical in prostate cancer patients.

July 9, 2026

AI ultrasound model accurately estimates gestational age

By Amerigo Allegretto

The model achieved noninferiority compared to standard clinical assessments in healthcare settings based in the U.S. and Africa.

July 9, 2026

Ultrasound In Africa 400

Leo Cancer Care nets $65M to deploy proton therapy system

By AuntMinnie.com staff writers

Stanford Medicine used the system to treat a pediatric brain tumor patient on June 4.

July 8, 2026

GE HealthCare, Mayo Clinic begin new theranostics trial in Minnesota

By AuntMinnie.com staff writers

First U.S. site to investigate the StarGuide GX SPECT/CT technology.

July 8, 2026

Atom Nuclear Lab Thumb

Philips launches new ultrasound system

By AuntMinnie.com staff writers

The system features AI-powered workflows and is designed for high-volume clinical environments.

July 8, 2026

AR-guided localization may sub for CT for early-stage lung cancer

By Amerigo Allegretto

AR-guided localization was noninferior to conventional CT guidance and led to better patient experiences.

July 8, 2026

Lungs 3 D Research 400

Imagion extends collaboration with Siemens on MRI contrast agent

By AuntMinnie.com staff writers

Siemens will provide in-kind expertise and technical support to clinical sites.

July 8, 2026

Study backs LDCT lung cancer screening in Singapore

Lung cancer is the leading cause of cancer death in Singapore, with approximately 48% of cases occurring in individuals who have never smoked.

July 8, 2026

New criteria evaluates treatment response in bone metastases

RECIBM-defined response classifications showed high agreement with established criteria and reclassified 19% of patients.

July 7, 2026

Response Evaluation Criteria in Bone Metastases (RECIBM) and metabolic criteria were used to detect a complete response missed at anatomic assessment. A 76-year-old male patient presented with 1 month of hemoptysis and was diagnosed with small cell lung cancer and bone metastases. Baseline (July 2022) F-18 FDG-PET/CT images (A, maximum intensity projection image; B–E, axial images) demonstrate FDG-avid lesions in the left lamina of the first lumbar vertebra (L1) (straight yellow arrows; maximum standardized uptake value, 2.74; peak standardized uptake value normalized to lean body mass, 1.59) and left ilium (curved yellow arrows; maximum standardized uptake value, 3.68; peak standardized uptake value normalized to lean body mass, 2.28). After seven chemotherapy cycles (December 2022), follow-up PET/CT images (F, maximum intensity projection image; G–J, axial images) show complete metabolic resolution of bony lesions (L1: maximum standardized uptake value, 1.32, and peak standardized uptake value normalized to lean body mass, 0.85; left ilium: maximum standardized uptake value, 1.48, and peak standardized uptake value normalized to lean body mass, 0.82), without apparent osteolytic or osteoblastic changes at CT. Assessment was stable disease (SD) according to the University of Texas MD Anderson Cancer Center (MDA) criteria but complete response (CR) or complete metabolic response (CMR) according to RECIBM, PET Response Criteria in Solid Tumors (PERCIST), and European Organization for Research and Treatment of Cancer (EORTC) criteria. The patient was alive as of September 30, 2025.

Page 1 of 3778